treatments

A total of 23,825 patients have to wait longer than the maximum 6-month-period to undergo one of the 14 surgeries with a guaranteed waiting time, according to the Catalan Minister of Health, Boi Ruiz. In 2013, a total of 151,009 patients underwent one of these surgeries, 3,834 more than the previous year, which represents a 2.6% increase. The number of patients who still require one of these 14 procedures in December 2013 has increased by 6% and 4,261 people, reaching 75,075 with an average waiting time of 5.78 months. On the other hand, the waiting lists for all surgeries, including the 14 specific procedures, have fallen by about 7,000 people in 2013 compared to 2012.

At the HIV Vaccine World Congress, which is taking place in Barcelona between the 7^th and 10^th October, Catalan researchers presented a vaccine prototype that has proven to be effective in clinical studies conducted with mice and monkeys. The vaccine stimulates the creation of antibodies and attacks infected cells. The prototype has been created by the Catalan programme to develop a vaccine against HIV, HIVACAT. According to the programme’s Scientific Director, Christian Brander, the vaccine could eventually also be used as a therapeutic treatment.

A study developed by researchers from Barcelona’s Center of Regenerative Medicine and California’s Gene Expression Laboratory of the Salk Institute identified a mutation in the nucleus of human neural stem cells that is linked to Parkinson’s, which may help to diagnose the disease and open a new field for targeted treatments. The prestigious journal ‘Nature’ published the study, which could also help to explain why the Parkinson’s disease is often associated with clinical depression and anxiety. The Center of Regenerative Medicine in Barcelona is directed by Juan Carlos Izpisúa, who participated in the study; it is located in the Barcelona Biomedical Research Park, next to the Hospital del Mar.

This world important discovery should open new paths to develop new drugs and to ultimately find a vaccine against HIV/AIDS. The finding has been published in the international journal PLoS Biology. The study has been funded by the Spanish Government, the Catalan Government, La Caixa savings bank, Barcelona’s Hospital Clínic and Esteve Labs.

The vaccine MVA-B against HIV gets a 90% immune response in its first test with humans. In addition, after a year, the vaccine proves to still be effective in 85% of the individuals. The vaccine is still a prototype but it shows a promising perspective. Soon it will be tested as well as a therapeutic vaccine, for people already infected with HIV-AIDS. The vaccine has been developed by the Spanish High Council of Scientific Research (CSIC), in collaboration with Barcelona’s Hospital Clínic and by Madrid’s Hospital Gregorio Marañón.

The new drug, called ‘Eribulin’, improves the survival rate of patients with a metastasis from breast cancer by 20%. The drug has been developed by a multinational team lead by staff from Barcelona’s Vall d’Hebron Hospital. The study has been published in the reference medical journal ‘The Lancet’.

Hospital Clinic will be the first Catalan medical centre to provide cells for clinical use to fight some pathologies. The hospital has received the European certificate allowing such practices.